Carries a disruption of the Abcg2 gene (ATP-binding cassette, sub-family G, member 2), formerly referred to as Bcrp
Altered drug transport capabilities due to ABC transporter protein deficiency
Bcrp functions as an efficient pharmacological barrier expressed in the apical membrane of epithelial cells of the small intestine, colon, cecum, and renal proximal tubules, in hepatic bile canalicular membranes, in mammary gland alveolar epithelial cells during pregnancy and lactation, and in placental labyrinth cells
Bcrp actively transports various anticancer drugs causing multi-drug resistance when expressed in cancer cells
Homozygote develops phototoxicity upon exposure to pheophorbide a, a chlorophyll metabolite, first expressed as ear lesions and can progress to mice becoming moribund
Homozygotes also displays a novel type of protoporphyria characterized by elevated levels of protoporphrin IX
Useful for studies of ATP-dependent transporters in vivo drug disposition and in inflammatory studies
The Bcrp mouse was developed in the laboratory of Alfred Schinkel of the Netherlands Cancer Institute in 2002. The model was created by targeting the Abcg2 gene in E14 embryonic stem cells derived from 129P2/OlaHsd mice and injecting the targeted cells into FVB blastocysts. Resultant chimeras were backcrossed to FVB/N for seven generations (N7). Taconic received stock in July 2003. The mice were derived by embryo transfer and are maintained by incrossing of homozygous mice.
Wild type for Nnt mutation; carries Pde6brd1 mutation
Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, Schinkel AH. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA, 99(24):15649-54.